Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ChanTest Announces ChansPorter™ Assays to Accelerate Drug Development

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
ChansPorter™ Assays provide the best means possible for measuring the functional activity of important pharmaceutical targets, including the Cystic Fibrosis Transmembrane conductance Regulator (CFTR).

The new ChansPorter™ Assays provide faster and more accurate answers. Using human (patient-derived) bronchial epithelia, and incorporating higher throughput into the discovery screening and profiling processes increases productivity several fold by eliminating false positives and negatives arising from animal cell lines. Time-to-results also is shortened significantly, saving time and cost.

In a Cystic Fibrosis (CF) patient, the CF gene tells the individual’s epithelial cells to produce a defective version of the CFTR protein, which causes the mucus that lines the lungs (and other organs) to become thickened and sticky. Impaired epithelial transport function results in chronic disease that reduces quality of life and life expectancy.

In the process of drug discovery, a better understanding of the function of a target protein like CFTR in disease leads to the development of better drug candidates.

When considering epithelial diseases like CF, functional assays for measuring drug effects on the activity of electrogenic transporters (that mediate fluid transport or flow) play an important role.

The Ussing Chamber Assay (UCA) is an established electrophysiological assay that uses epithelial voltage clamp technology to evaluate electrogenic transporter activity and measure net fluid transport, electrolyte, nutrient and drug transport across epithelial tissues.

The UCA has been used to measure ex vivo (tissue) transport activity in essentially all epithelia. Cultured epithelial cells (primary and cell lines) capable of forming polarized epithelia (epithelia which allow the tissue to secrete or absorb fluid) are used extensively in in vitro UCAs for functional evaluations in drug discovery, physiology and toxicology.

“We have a highly-skilled team of cell biologists and electrophysiologists at ChanTest working on the Ussing Assay for drug discovery clients,” said Dr. Antonio Lacerda, Director of Contract Research & Development Services at ChanTest.

Dr. Lacerda continued, “Now, building on this technology, with ChansPorter Assays, I believe that we have the highest throughput in the industry, and a strong, high-quality capability for measuring important epithelial targets, such as CFTR.”

ChanTest regularly performs high-quality experiments on an unprecedented scale.

ChansPorter Assays include three independent 24-chamber Ussing systems dedicated to CF, R&D and contract research testing with the capacity to simultaneously test 72 epithelia grown on SnapWell™ filter inserts.

A fourth 24-chamber system is used for cGMP compliant release assays.

ChanTest employs a higher throughput embodiment of the UCA with a semi-automated system that utilizes a robot, a 24-channel epithelial voltage clamp (TECC-24) and 24-well microplates containing CFhBE (Cystic Fibrosis human Bronchial Epithelia) grown on permeable support for up to five times the throughput of the 24-chamber systems.

The epithelia are derived from cultures of patient primary cells or cell lines (of both human and animal origin).

There is an urgent need to accelerate the identification of new solutions in drug discovery for cystic fibrosis patients.

ChansPorter™ Assays provide the industry with a way to more quickly and accurately assess the best drug candidates by measuring the functional activity of important pharmaceutical targets, including CFTR.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ChanTest Acquires Applied Cell Sciences
Expanded drug discovery and development services, cell lines, and reagents now cover nearly half of the known drugable genome.
Friday, February 27, 2009
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!